88 results
This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of RO7284755 (alone or incombination with atezolizumab) and to evaluate its anti-tumor activity.
To evaluate the efficacy and safety of EHSG-KF in comparison to meshed STSG in children with partial deep dermal and full thickness burns. Primary Objective: To evaluate the efficacy of EHSG-KF in comparison to meshed STSG based on:• Ratio of…
The primary objective of this study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to…
To evaluate the efficacy and safety of EHSG-KF in comparison to meshed STSG in adults and adolescents with partial deep dermal and full thickness burns.Primary Objective: To evaluate the efficacy ofEHSG-KF in comparison to meshed STSG based on:•…
In our phase IIa trial we will determine the effect and safety of three MABs administrations in the m. biceps brachii in m.3243A>G patients with a functional deficit in this muscle. The phase IIa trial will consist of three administrations of…
The primary endpoint is the evaluation of the safety and toxicity of TIL with nivolumab and, thereafter, the safety and toxicity of the combination of PEG-IFNa, nivolumab plus TIL. Safety and toxicity will be evaluated according to CTCAE 4.0…
To evaluate the efficacy and safety of EHSG-KF in comparison to STSG (unmeshed or meshed up to 1:3) in adults and children with large full thickness skin defects.Primary Objective:To evaluate the efficacy of EHSG-KF in comparison to STSG based on…
Primary:- To evaluate the short-term safety and tolerability of TX200-TR101 from the day of TX200 TR101 infusion within 28 days post TX200 TR101 infusion.Key Secondary: Clinical- To evaluate the effect of TX200 TR101 on acute graft-related outcomes…